Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy

Alexander Kutikov, Robert G. Uzzo, Aaron Caraway, Carl T. Reese, Brian L. Egleston, David Y T Chen, Rosalia Viterbo, Richard E. Greenberg, Yu Ning Wong, Jay D. Raman, Stephen A. Boorjian

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

OBJECTIVE To present a multi-institutional experience evaluating the use of systemic therapy in patients undergoing cytoreductive nephrectomy (CN), as prospective randomized trials showed a survival benefit for CN in patients with metastatic renal cell carcinoma treated with immunotherapy, and these data have been extrapolated to support CN in the era of targeted therapy, but the likelihood that patients with metastatic kidney cancer who undergo CN will receive systemic treatment afterward remains poorly defined. PATIENTS AND METHODS In all, 141 patients who underwent CN between 1990 and 2008 were identified from our Institutional Kidney Cancer Registries. Kaplan-Meier analyses and Cox regression models were used to assess the effect of clinicopathological and perioperative variables on patients' subsequent receipt of systemic therapy, and survival after CN. RESULTS Overall, 98 of the 141 patients (69.5%) received postoperative systemic treatment, at a median (range) of 2.5 (0.1-61.5) months after CN. In this group, 52 (53%) patients received immunotherapy, 34 (35%) targeted agents, and 12 (12%) other regimens. By contrast, 43 patients (31%) did not receive systemic therapy, because of rapid disease progression (13, 30%), decision for surveillance by medical oncology (nine, 21%), patient refusal (10, 23%), perioperative death (eight, 19%), and unknown reasons in three (7%). The median (range) survival after CN was 16.7 (0-120) months. The risk of death after surgery correlated with the number of metastatic sites (P = 0.012) and symptoms (P = 0.001) at presentation, poor performance status (P = 0.001), high tumour grade (P = 0.006), and presence of sarcomatoid features (P < 0.024). CONCLUSION Nearly a third of patients undergoing CN did not receive systemic treatment. While some were electively observed or declined therapy, others did not receive treatment due to rapidly progressive disease. Further investigation is warranted to identify those patients at highest risk of rapid postoperative disease progression who might benefit instead from an initial approach to treatment with systemic therapy.

Original languageEnglish (US)
Pages (from-to)218-223
Number of pages6
JournalBJU International
Volume106
Issue number2
DOIs
StatePublished - Jul 2010
Externally publishedYes

Fingerprint

Nephrectomy
Survival
Therapeutics
Kidney Neoplasms
Immunotherapy
Disease Progression
Medical Oncology
Kaplan-Meier Estimate
Renal Cell Carcinoma
Proportional Hazards Models
Registries

Keywords

  • metastases
  • nephrectomy
  • renal cell carcinoma
  • systemic therapy
  • targeted therapy

ASJC Scopus subject areas

  • Urology

Cite this

Kutikov, A., Uzzo, R. G., Caraway, A., Reese, C. T., Egleston, B. L., Chen, D. Y. T., ... Boorjian, S. A. (2010). Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU International, 106(2), 218-223. https://doi.org/10.1111/j.1464-410X.2009.09079.x

Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. / Kutikov, Alexander; Uzzo, Robert G.; Caraway, Aaron; Reese, Carl T.; Egleston, Brian L.; Chen, David Y T; Viterbo, Rosalia; Greenberg, Richard E.; Wong, Yu Ning; Raman, Jay D.; Boorjian, Stephen A.

In: BJU International, Vol. 106, No. 2, 07.2010, p. 218-223.

Research output: Contribution to journalArticle

Kutikov, A, Uzzo, RG, Caraway, A, Reese, CT, Egleston, BL, Chen, DYT, Viterbo, R, Greenberg, RE, Wong, YN, Raman, JD & Boorjian, SA 2010, 'Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy', BJU International, vol. 106, no. 2, pp. 218-223. https://doi.org/10.1111/j.1464-410X.2009.09079.x
Kutikov, Alexander ; Uzzo, Robert G. ; Caraway, Aaron ; Reese, Carl T. ; Egleston, Brian L. ; Chen, David Y T ; Viterbo, Rosalia ; Greenberg, Richard E. ; Wong, Yu Ning ; Raman, Jay D. ; Boorjian, Stephen A. / Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. In: BJU International. 2010 ; Vol. 106, No. 2. pp. 218-223.
@article{e20bc0c9ac5a4884aad1bc40d0ca48d2,
title = "Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy",
abstract = "OBJECTIVE To present a multi-institutional experience evaluating the use of systemic therapy in patients undergoing cytoreductive nephrectomy (CN), as prospective randomized trials showed a survival benefit for CN in patients with metastatic renal cell carcinoma treated with immunotherapy, and these data have been extrapolated to support CN in the era of targeted therapy, but the likelihood that patients with metastatic kidney cancer who undergo CN will receive systemic treatment afterward remains poorly defined. PATIENTS AND METHODS In all, 141 patients who underwent CN between 1990 and 2008 were identified from our Institutional Kidney Cancer Registries. Kaplan-Meier analyses and Cox regression models were used to assess the effect of clinicopathological and perioperative variables on patients' subsequent receipt of systemic therapy, and survival after CN. RESULTS Overall, 98 of the 141 patients (69.5{\%}) received postoperative systemic treatment, at a median (range) of 2.5 (0.1-61.5) months after CN. In this group, 52 (53{\%}) patients received immunotherapy, 34 (35{\%}) targeted agents, and 12 (12{\%}) other regimens. By contrast, 43 patients (31{\%}) did not receive systemic therapy, because of rapid disease progression (13, 30{\%}), decision for surveillance by medical oncology (nine, 21{\%}), patient refusal (10, 23{\%}), perioperative death (eight, 19{\%}), and unknown reasons in three (7{\%}). The median (range) survival after CN was 16.7 (0-120) months. The risk of death after surgery correlated with the number of metastatic sites (P = 0.012) and symptoms (P = 0.001) at presentation, poor performance status (P = 0.001), high tumour grade (P = 0.006), and presence of sarcomatoid features (P < 0.024). CONCLUSION Nearly a third of patients undergoing CN did not receive systemic treatment. While some were electively observed or declined therapy, others did not receive treatment due to rapidly progressive disease. Further investigation is warranted to identify those patients at highest risk of rapid postoperative disease progression who might benefit instead from an initial approach to treatment with systemic therapy.",
keywords = "metastases, nephrectomy, renal cell carcinoma, systemic therapy, targeted therapy",
author = "Alexander Kutikov and Uzzo, {Robert G.} and Aaron Caraway and Reese, {Carl T.} and Egleston, {Brian L.} and Chen, {David Y T} and Rosalia Viterbo and Greenberg, {Richard E.} and Wong, {Yu Ning} and Raman, {Jay D.} and Boorjian, {Stephen A.}",
year = "2010",
month = "7",
doi = "10.1111/j.1464-410X.2009.09079.x",
language = "English (US)",
volume = "106",
pages = "218--223",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy

AU - Kutikov, Alexander

AU - Uzzo, Robert G.

AU - Caraway, Aaron

AU - Reese, Carl T.

AU - Egleston, Brian L.

AU - Chen, David Y T

AU - Viterbo, Rosalia

AU - Greenberg, Richard E.

AU - Wong, Yu Ning

AU - Raman, Jay D.

AU - Boorjian, Stephen A.

PY - 2010/7

Y1 - 2010/7

N2 - OBJECTIVE To present a multi-institutional experience evaluating the use of systemic therapy in patients undergoing cytoreductive nephrectomy (CN), as prospective randomized trials showed a survival benefit for CN in patients with metastatic renal cell carcinoma treated with immunotherapy, and these data have been extrapolated to support CN in the era of targeted therapy, but the likelihood that patients with metastatic kidney cancer who undergo CN will receive systemic treatment afterward remains poorly defined. PATIENTS AND METHODS In all, 141 patients who underwent CN between 1990 and 2008 were identified from our Institutional Kidney Cancer Registries. Kaplan-Meier analyses and Cox regression models were used to assess the effect of clinicopathological and perioperative variables on patients' subsequent receipt of systemic therapy, and survival after CN. RESULTS Overall, 98 of the 141 patients (69.5%) received postoperative systemic treatment, at a median (range) of 2.5 (0.1-61.5) months after CN. In this group, 52 (53%) patients received immunotherapy, 34 (35%) targeted agents, and 12 (12%) other regimens. By contrast, 43 patients (31%) did not receive systemic therapy, because of rapid disease progression (13, 30%), decision for surveillance by medical oncology (nine, 21%), patient refusal (10, 23%), perioperative death (eight, 19%), and unknown reasons in three (7%). The median (range) survival after CN was 16.7 (0-120) months. The risk of death after surgery correlated with the number of metastatic sites (P = 0.012) and symptoms (P = 0.001) at presentation, poor performance status (P = 0.001), high tumour grade (P = 0.006), and presence of sarcomatoid features (P < 0.024). CONCLUSION Nearly a third of patients undergoing CN did not receive systemic treatment. While some were electively observed or declined therapy, others did not receive treatment due to rapidly progressive disease. Further investigation is warranted to identify those patients at highest risk of rapid postoperative disease progression who might benefit instead from an initial approach to treatment with systemic therapy.

AB - OBJECTIVE To present a multi-institutional experience evaluating the use of systemic therapy in patients undergoing cytoreductive nephrectomy (CN), as prospective randomized trials showed a survival benefit for CN in patients with metastatic renal cell carcinoma treated with immunotherapy, and these data have been extrapolated to support CN in the era of targeted therapy, but the likelihood that patients with metastatic kidney cancer who undergo CN will receive systemic treatment afterward remains poorly defined. PATIENTS AND METHODS In all, 141 patients who underwent CN between 1990 and 2008 were identified from our Institutional Kidney Cancer Registries. Kaplan-Meier analyses and Cox regression models were used to assess the effect of clinicopathological and perioperative variables on patients' subsequent receipt of systemic therapy, and survival after CN. RESULTS Overall, 98 of the 141 patients (69.5%) received postoperative systemic treatment, at a median (range) of 2.5 (0.1-61.5) months after CN. In this group, 52 (53%) patients received immunotherapy, 34 (35%) targeted agents, and 12 (12%) other regimens. By contrast, 43 patients (31%) did not receive systemic therapy, because of rapid disease progression (13, 30%), decision for surveillance by medical oncology (nine, 21%), patient refusal (10, 23%), perioperative death (eight, 19%), and unknown reasons in three (7%). The median (range) survival after CN was 16.7 (0-120) months. The risk of death after surgery correlated with the number of metastatic sites (P = 0.012) and symptoms (P = 0.001) at presentation, poor performance status (P = 0.001), high tumour grade (P = 0.006), and presence of sarcomatoid features (P < 0.024). CONCLUSION Nearly a third of patients undergoing CN did not receive systemic treatment. While some were electively observed or declined therapy, others did not receive treatment due to rapidly progressive disease. Further investigation is warranted to identify those patients at highest risk of rapid postoperative disease progression who might benefit instead from an initial approach to treatment with systemic therapy.

KW - metastases

KW - nephrectomy

KW - renal cell carcinoma

KW - systemic therapy

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77953821449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953821449&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2009.09079.x

DO - 10.1111/j.1464-410X.2009.09079.x

M3 - Article

VL - 106

SP - 218

EP - 223

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2

ER -